Monte Rosa Therapeutics appoints Jan Skvarka to Board of Directors

Monte Rosa Therapeutics, Inc.

Appointed Jan Skvarka, Ph.D., MBA to the Board, effective March 23, 2023.
Skvarka will serve as a Class I director until the 2025 annual meeting.
Board determined Skvarka is independent under Nasdaq listing standards.
Compensation follows Non-Employee Director Compensation Policy; entered indemnification agreement.
No arrangements or transactions requiring disclosure under Item 404(a) of Regulation S-K.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jan Skvarka

Director

GLUE · Monte Rosa Therapeutics, Inc.

Effective: 2023-03-23
Filed: March 23, 2023, 7:59 PM ET

the Board appointed Jan Skvarka, Ph.D., MBA to join the Board, effective as of March 23, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jan Skvarka was appointed as Director at Monte Rosa Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board appointed Jan Skvarka, Ph.D., MBA to join the Board, effective as of March 23, 2023.

View on SEC.gov

Monte Rosa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-009320

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.